Story perspectives

Trump Orders $50M Psychedelic Research Boost, Texas Starts Ibogaine Trials

4/24/2026

Summary

Story summary

President Donald Trump signed an executive order on April 18, 2026 after a Joe Rogan text, directing FDA, DEA and VA to prioritize psychedelic research and allocate $50 million.
The order earmarks $50 million for state studies, and Texas will use its share for ibogaine trials under Senate Bill 2308.
A 2024 Stanford Medicine trial of 30 veterans reported PTSD, depression and anxiety reductions after an ibogaine session, though experts warn of cardiac risks.

History

Historical Context

The Controlled Substances Act of 1970 classified psychedelics like ibogaine as Schedule I drugs, hindering research. With over 30% of veterans facing PTSD, President Trump's 2026 executive order allocated $50 million for psychedelic research, reflecting a policy shift. This follows Oregon's 2020 legalization of psilocybin for mental health treatment, signaling a potential transformation in veteran care and drug regulation.

1 of 2

Story summary

President Donald Trump signed an executive order on April 18, 2026 after a Joe Rogan text, directing FDA, DEA and VA to prioritize psychedelic research and allocate $50 million.
The order earmarks $50 million for state studies, and Texas will use its share for ibogaine trials under Senate Bill 2308.
A 2024 Stanford Medicine trial of 30 veterans reported PTSD, depression and anxiety reductions after an ibogaine session, though experts warn of cardiac risks.

1 / 2